Cargando…

FIB‑4 index and serum α‑fetoprotein are useful predictors of hepatocellular carcinoma occurrence in hepatitis B patients with nucleos(t)ide analogs therapy

Current antiviral therapies cannot achieve eradication of hepatitis B virus (HBV) and can reduce but not eliminate the risk of hepatocellular carcinoma (HCC) in patients with chronic HBV infection. The present study aimed to identify the risk factors for HCC development by analyzing nucleoside analo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuwano, Akifumi, Miyazaki, Masayuki, Yada, Masayoshi, Tanaka, Kosuke, Koga, Yuta, Masumoto, Akihide, Motomura, Kenta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443030/ https://www.ncbi.nlm.nih.gov/pubmed/37614433 http://dx.doi.org/10.3892/etm.2023.12140

Ejemplares similares

Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice
por: Motomura, Kenta, et al.
Publicado: (2023)

Risk factors for loss to follow‐up after the start of direct‐acting antiviral treatment for hepatitis C virus infection
por: Kuwano, Akifumi, et al.
Publicado: (2022)

Tumor‑infiltrating CD8(+) T cells as a biomarker for chemotherapy efficacy in unresectable hepatocellular carcinoma
por: Kuwano, Akifumi, et al.
Publicado: (2023)

Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus
por: Yada, Masayoshi, et al.
Publicado: (2018)

Therapeutic efficacy of lenvatinib for hepatocellular carcinoma with iso-high intensity in the hepatobiliary phase of Gd-EOB-DTPA-MRI
por: Kuwano, Akifumi, et al.
Publicado: (2022)

Multicentric recurrence of intraductal papillary neoplasm of bile duct after spontaneous detachment of primary tumor: A case report
por: Fukuya, Hiroki, et al.
Publicado: (2022)

Therapeutic efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma with WNT/β-catenin signal activation
por: Kuwano, Akifumi, et al.
Publicado: (2022)

The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs
por: Gupta, Nidhi, et al.
Publicado: (2014)

Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma
por: Miyazaki, Masayuki, et al.
Publicado: (2017)

Impact of nucleos(t)ide analog treatment on the development of malignancy in patients with chronic hepatitis B
por: Kim, Soon Sun, et al.
Publicado: (2018)

Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs
por: Siakavellas, Spyros, et al.
Publicado: (2021)

Baseline Circulating miR-125b Levels Predict a High FIB-4 Index Score in Chronic Hepatitis B Patients after Nucleos(t)ide Analog Treatment
por: Wu, Jyun-Yi, et al.
Publicado: (2022)

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
por: Jung, Sang Kyung, et al.
Publicado: (2015)

Predictors of Sustained Virologic Response after Discontinuation of Nucleos(t)ide Analog Treatment for Chronic Hepatitis B
por: Peng, Jie, et al.
Publicado: (2015)

High percentage atypical hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs
por: Lin, Ching-Chung, et al.
Publicado: (2019)

Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas
por: Wei, Yanyan, et al.
Publicado: (2019)

Clinical features of hepatocellular carcinoma with hepatitis B virus among patients on Nucleos(t) ide analog therapy
por: Liu, Li
Publicado: (2020)

Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
por: Maisa, Anna, et al.
Publicado: (2021)

Antiviral activities of two nucleos(t)ide analogs against vaccinia and mpox viruses in primary human fibroblasts
por: Dsouza, Lara, et al.
Publicado: (2023)

Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population
por: López-Cortés, Luis F., et al.
Publicado: (2014)

Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog Therapy
por: Osiowy, Carla, et al.
Publicado: (2016)

Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs
por: Li, Tao, et al.
Publicado: (2018)

Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss
por: Xue, Yan, et al.
Publicado: (2021)

The 96-week clinical outcomes after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients
por: Xu, Wen-Xiong, et al.
Publicado: (2021)

Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog
por: Hui, Vicki Wing-Ki, et al.
Publicado: (2021)

Corrigendum: Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
por: Maisa, Anna, et al.
Publicado: (2022)

Antiviral activities of two nucleos(t)ide analogs against vaccinia, mpox, and cowpox viruses in primary human fibroblasts
por: Dsouza, Lara, et al.
Publicado: (2023)

Dynamics of Serum Pregenome RNA in Chronic Hepatitis B Patients Receiving 96-Month Nucleos(t)ide Analog Therapy
por: Tao, Yachao, et al.
Publicado: (2022)

Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B
por: Kim, Soon Sun, et al.
Publicado: (2011)

Frequency and Mutation Patterns of Resistance in Patients with Chronic Hepatitis B Infection Treated with Nucleos(t)ide Analogs in Add-On and Switch Strategies
por: Sayan, Murat, et al.
Publicado: (2011)

The efficiency of low-dose hepatitis B immunoglobulin plus nucleos(t)ide analogs in preventing posttransplant hepatitis B virus recurrence
por: VATANSEVER, Sezgin, et al.
Publicado: (2019)

The Impact of Nucleos(t)ide Analogs Off-Therapy Among Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis
por: Wang, Mian, et al.
Publicado: (2021)

The Effects of the National Centralized Drug Purchasing Pilot Program on Nucleos(t)ide Analogs in Shenzhen City: An Interrupted Time Series Analysis
por: Wen, Xiaotong, et al.
Publicado: (2021)

Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B
por: Lee, I-Cheng, et al.
Publicado: (2015)

Selected nucleos(t)ide-based prescribed drugs and their multi-target activity
por: Pastuch-Gawołek, Gabriela, et al.
Publicado: (2019)

Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients
por: Zhang, Chi, et al.
Publicado: (2016)

Renal Function in Nucleos(t)ide Analog-Treated Patients With Chronic Hepatitis B: A Systematic Literature Review and Network Meta-Analysis
por: Chan, Henry L. Y., et al.
Publicado: (2016)

Hepatocellular Carcinoma in Chronic Hepatitis B Patients on Third Generation Nucleos(t)ides Analogs: Risk Factors and Performance of a Risk Score
por: Magalhães-Costa, Pedro, et al.
Publicado: (2016)

Circulating miR-122 Is a Predictor for Virological Response in CHB Patients With High Viral Load Treated With Nucleos(t)ide Analogs
por: Wu, Yin, et al.
Publicado: (2019)

Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis B during nucleos(t)ide analog therapy
por: Murata, Ayato, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_97nr71rqvhp2e2125agk40nrdb